OVARIAN NEOPLASMS
Clinical trials for OVARIAN NEOPLASMS explained in plain language.
Never miss a new study
Get alerted when new OVARIAN NEOPLASMS trials appear
Sign up with your email to follow new studies for OVARIAN NEOPLASMS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug targets HER2-Positive tumors in multiple cancers
Disease control OngoingThis phase 2 trial tests an experimental drug called disitamab vedotin in people with advanced head and neck, lung, endometrial, or ovarian cancers that have a protein called HER2. The drug is designed to stick to cancer cells and kill them. Researchers want to see if it shrinks …
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug targets rare cancer mutation in early trial
Disease control OngoingThis early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE1 • Sponsor: Atavistik Bio, Inc • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New pill targets hard-to-treat cancers with KRAS mutation
Disease control OngoingThis study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Ovarian cancer hope: new antibody combo aims to delay disease worsening
Disease control OngoingThis Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill may keep ovarian cancer at bay after chemo
Disease control OngoingThis study tests whether a daily pill called niraparib can help keep advanced ovarian cancer from coming back after initial chemotherapy. About 733 women with stage III or IV ovarian cancer who responded to platinum-based chemo took either niraparib or a placebo. The main goal wa…
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug cocktail shows promise in battle against advanced ovarian cancer
Disease control OngoingThis study tests whether adding two newer drugs (dostarlimab and niraparib) to standard chemotherapy helps people with advanced ovarian cancer live longer without their cancer growing. About 1,400 participants with stage III or IV ovarian cancer will receive either the standard t…
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Ovarian cancer vaccine trial aims to keep tumors at bay
Disease control OngoingThis study tests a personalized immunotherapy called Vigil in 92 women with advanced ovarian cancer who are currently cancer-free after surgery and chemotherapy. The treatment uses the patient's own tumor cells to create a vaccine that trains the immune system to fight any remain…
Matched conditions: OVARIAN NEOPLASMS
Phase: PHASE2 • Sponsor: Gradalis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
DNA bank aims to unlock secrets of family cancer clusters
Knowledge-focused OngoingThis study collects blood and saliva samples from people with cancer and their relatives to build a DNA bank. Researchers hope to better understand how cancer runs in families. About 992 participants are expected to join. The samples will be stored and analyzed later for genetic …
Matched conditions: OVARIAN NEOPLASMS
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC